84539-30-0

Basic information

• Product Name: 5-BROMO-N-METHYLPYRIDIN-2-AMINE
• Synonyms: 5-BROMO-N-METHYLPYRIDIN-2-AMINE;5-Bromo-2-(N-methylamino)pyridine;5-bromo-N-methyl-2-pyridinamine(SALTDATA: FREE);2-(Methylamino)-5-bromopyridine;N-Methyl-5-bromopyridine-2-amine;2-PyridinaMine, 5-broMo-N-Methyl-
• CAS NO: 84539-30-0
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• Mol File: 84539-30-0.mol
• Article Data: 16

Chemical Properties

• Melting Point: 70-71 °C
• Boiling Point: 245℃
• Flash Point: 102℃
• Appearance: /
• Density: 1.581
• Storage Temp.: Room temperature.
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 5.00±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-N-METHYLPYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-N-METHYLPYRIDIN-2-AMINE(84539-30-0)
• EPA Substance Registry System: 5-BROMO-N-METHYLPYRIDIN-2-AMINE(84539-30-0)

Safety Data

• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 84539-30-0(Hazardous Substances Data)

Usage

Uses

5-Bromo-2-(N-methylamino)pyridine is useful for the synthetic preparation of halo aminopyridines.

InChI:InChI=1S/C6H7BrN2/c1-8-6-3-2-5(7)4-9-6/h2-4H,1H3,(H,8,9)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 28539-02-8 1-Hydroxymethyl-1H-benzotriazole 
• 157020-26-3 pyridinium N-<2'-(5'-bromopyridyl)>aminide 
• 67-56-1 methanol 
• 53939-30-3 5-bromo-2-chloropyridine 
• 593-51-1 methylamine hydrochloride 
• 74-88-4 methyl iodide 
• 624-28-2 2,5-dibromopyridine 
• 4597-87-9 2-(N-methylamino)pyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 74-89-5 methylamine 

Downstream Products

• 227939-01-7 5-bromo-2-(N-methyl-N-(t-butoxycarbonyl)amino)pyridine 
• 1005009-98-2 methyl-[5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)pyridin-2-yl]amine 
• 1032758-87-4 methyl-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-carbamic acid tert-butyl ester 
• 1235449-52-1 N-hydroxy-2-(methyl((2-(6-(methylamino)pyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)amino)pyrimidine-5-carboxamide 
• 1613169-20-2 ethyl 2-(4-(6-(methylamino)pyridin-3-yl)phenoxy)acetate 
• 1613168-96-9 4-(6-(methylamino)pyridin-3-yl)phenol 
• 1360551-39-8 2-[4-(3-{1-cyclopropyl-1-[4-(6-methylamino-pyridin-3-yl)-phenyl]-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide 
• 1360551-68-3 2-[4-(3-{(R)-1-cyclopropyl-1-[4-(6-methylamino-pyridin-3-yl)-phenyl]-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide 
• 261715-36-0 6-(methylamino)nicotinonitrile 
• 1267851-49-9 N-(5-tert-butylisoxazol-3-yl)-2-(4-(6-(methylamino)pyridin-3-yl)phenyl)acetamide 
• 152684-20-3 N-methyl-3-nitro-5-phenylpyridin-2-amine 

Relevant articles and documents

Directing Group Enables Electrochemical Selectively Meta-Bromination of Pyridines under Mild Conditions

Without the use of catalysts and oxidants, a facile and sustainable electrochemical bromination protocol was developed. By introducing the directing groups, the regioselectivity of pyridine derivatives could be controlled at themeta-position utilizing the inexpensive and safe bromine salts at room temperature. A variety of brominated pyridine derivatives were obtained in 28-95% yields, and the reaction could be readily performed at a gram scale. By combining the installation and removing the directing group, the concept ofmeta-bromination of pyridines could be verified.

Thiophene pyrimidines and preparation and its preparation method and application

The invention discloses a pyrantel compound and preparation, as well as a preparation method and application of the pyrantel compound and preparation, belonging to the technical field of chemical medicines and preparations thereof. According to the pyrantel compound or pharmaceutically acceptable salt thereof, HDAC (histone deacetylase)/PI3K (phosphatidylinositide 3-kinase) double-target inhibitor is used for selectively inhibiting tumor cell messenger core protein kinase target PI3K and epigenetic target HDAC which are synergized, and is capable of destroying the network of tumor cell messengers, thus exerting a great killing effect on various tumor cells. In multiple blood and entity heterogenic transplanted tumor animal models, the inhibitor can be used for intensively effectively inhibiting tumor growth and especially has a remarkable effect on various blood B-cell malignant tumors, and safety evaluation tests indicate that the inhibitor has high safety and security. The pyrantel compound and preparation can be used for effectively treating patients with later reoccurrence of lymphoma, myeloma and lymphatic leukemia or drug resistance.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.